Key result
Cardiovascular medications during pregnancy demand multidisciplinary management tailored to physiological and pharmacological changes.
Why the study?
Cardiovascular disease complicating pregnancy is increasing due to advanced maternal age, cardiovascular risk factors, and improved congenital heart disease management, requiring understanding of drug effects during pregnancy.
Management of cardiovascular medications in pregnant women requires understanding of altered pharmacokinetics and a multidisciplinary team approach.
Cardiovascular disease complicating pregnancy is rising in prevalence secondary to advanced maternal age, cardiovascular risk factors, and the successful management of congenital heart disease conditions. The physiological changes of pregnancy may alter drug properties affecting both mother and fetus. Familiarity with both physiological and pharmacological attributes is key for the successful management of pregnant women with cardiac disease. This review summarizes the published data, available guidelines, and recommendations for use of cardiovascular medications during pregnancy. Care of the pregnant woman with cardiovascular disease requires a multidisciplinary team approach with members from cardiology, maternal fetal medicine, anesthesia, and nursing.
No takes yet. Share an insight, caveat, or question.
Halpern et al. (2019) conducted a review in Cardiovascular disease during pregnancy. Cardiovascular medications was evaluated. The use of cardiovascular medications during pregnancy requires familiarity with physiological and pharmacological changes and a multidisciplinary team approach for successful management.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: